Secondary Progressive Multiple Sclerosis Clinical Trial
Official title:
A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
This will be a single site 1:1 randomized, placebo controlled trial of metformin treatment vs matching placebo in 44 men and women with primary progressive multiple sclerosis and secondary multiple sclerosis, without diabetes, not treated with metformin aged 30-65. The trial will last 12 months and have 3 study visits, baseline, 6 months, and 12 months. The trial will be preceded by a screening period. Over the initial 30 day titration period subjects will be titrated from 500 mg a day to 2,000 mg of metformin in increments of 500 mg every 10 days. Patients will remain on their tolerated dose and included in analysis on an intent to treat basis. Brain MRI, cognitive testing and clinical measures will be collected at baseline, month 6 and month 12. OCT will be collected at baseline and month 12. The primary outcomes are the following safety outcomes: 1) number of patients with adverse events 2) number of patients with laboratory abnormalities 3) number of patients with new T2 lesions on MRI. The secondary outcomes include reduction in localized cortical thinning on brain MRI; reduction in thalamic atrophy on brain MRI. Further exploratory outcomes include 1) improvement in SDMT-oral score, 2) improvement in CVLT-II score, 3) improvement in PACC score 4) improvement in PASAT score. Exploratory outcomes include 1) Decrease in plasma neurofilament light chain levels, 2) Reginal nerve fiber layer preservation on OCT, 3) Ganglion cell inner plexiform layer preservation, and 4) Percentage of phase rim lesions. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04239664 -
Acceptance Based Telephone Support When Transitioning to SPMS
|
N/A | |
Active, not recruiting |
NCT04411641 -
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
|
Phase 3 | |
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Terminated |
NCT01416181 -
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
Withdrawn |
NCT01181089 -
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
Withdrawn |
NCT05029609 -
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
|
Phase 1 | |
Terminated |
NCT02296346 -
Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT02228213 -
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
Terminated |
NCT03283826 -
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02253264 -
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT01737372 -
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
|
N/A | |
Completed |
NCT00257855 -
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT06292923 -
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
|
Phase 2 | |
Active, not recruiting |
NCT01228396 -
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT03896217 -
Simvastatin in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02495766 -
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT00813969 -
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
|
Phase 1 | |
Completed |
NCT01077466 -
Natalizumab Treatment of Progressive Multiple Sclerosis
|
Phase 2 |